Peripheral Blood DNA Methylation–Based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biologic Specimens and Data From the Osteoarthritis Initiative and Johnston County Osteoarthritis Project

Objective The lack of accurate biomarkers to predict knee osteoarthritis (OA) progression is a key unmet need in OA clinical research. The objective of this study was to develop baseline peripheral blood epigenetic biomarker models to predict knee OA progression. Methods Genome‐wide buffy coat DNA m...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 75; no. 1; pp. 28 - 40
Main Authors Dunn, Christopher M., Sturdy, Cassandra, Velasco, Cassandra, Schlupp, Leoni, Prinz, Emmaline, Izda, Vladislav, Arbeeva, Liubov, Golightly, Yvonne M., Nelson, Amanda E., Jeffries, Matlock A.
Format Journal Article
LanguageEnglish
Published Boston, USA Wiley Periodicals, Inc 01.01.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN2326-5191
2326-5205
2326-5205
DOI10.1002/art.42316

Cover

More Information
Summary:Objective The lack of accurate biomarkers to predict knee osteoarthritis (OA) progression is a key unmet need in OA clinical research. The objective of this study was to develop baseline peripheral blood epigenetic biomarker models to predict knee OA progression. Methods Genome‐wide buffy coat DNA methylation patterns from 554 individuals from the Osteoarthritis Biomarkers Consortium (OABC) were determined using Illumina Infinium MethylationEPIC 850K arrays. Data were divided into model development and validation sets, and machine learning models were trained to classify future OA progression by knee pain, radiographic imaging, knee pain plus radiographic imaging, and any progression (pain, radiographic, or both). Parsimonious models using the top 13 CpG sites most frequently selected during development were tested on independent samples from participants in the Johnston County Osteoarthritis (JoCo OA) Project (n = 128) and a previously published Osteoarthritis Initiative (OAI) data set (n = 55). Results Full models accurately classified future radiographic‐only progression (mean ± SEM accuracy 87 ± 0.8%, area under the curve [AUC] 0.94 ± 0.004), pain‐only progression (accuracy 89 ± 0.9%, AUC 0.97 ± 0.004), pain plus radiographic progression (accuracy 72 ± 0.7%, AUC 0.79 ± 0.006), and any progression (accuracy 78 ± 0.4%, AUC 0.86 ± 0.004). Pain‐only and radiographic‐only progressors were not distinguishable (mean ± SEM accuracy 58 ± 1%, AUC 0.62 ± 0.001). Parsimonious models showed similar performance and accurately classified future radiographic progressors in the OABC cohort and in both validation cohorts (mean ± SEM accuracy 80 ± 0.3%, AUC 0.88 ± 0.003 [using JoCo OA Project data], accuracy 80 ± 0.8%, AUC 0.89 ± 0.002 [using previous OAI data]). Conclusion Our data suggest that pain and structural progression share similar early systemic immune epigenotypes. Further studies should focus on evaluating the pathophysiologic consequences of differential DNA methylation and peripheral blood cell epigenotypes in individuals with knee OA.
Bibliography:Author disclosures are available at
https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42316&file=art42316‐sup‐0001‐Disclosureform.pdf
A graphical abstract can be found in the online article at
Supported by the NIH (grants K08‐AR‐070891, P20‐GM‐125528, R61‐AR‐078075, and R01AR076440), along with the Congressionally Directed Medical Research Program (grant PR191652). The OAI is a public‐private partnership comprising 5 contracts (N01‐AR‐2‐2258, N01‐AR‐2‐2259, N01‐AR‐2‐2260, N01‐AR‐2‐2261, and N01‐AR‐2‐2262) funded by the NIH and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health.
The Johnston County Osteoarthritis Project is funded in part by the Association of Schools of Public Health (grants S043, S1734, S3486), Centers for Disease Control and Prevention (grants U01 DP003206 and U01 DP006266), and National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants P60AR30701, P60AR049465, P60AR064166, and P30AR072580).
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH nor the Department of Defense. This manuscript was prepared using an Osteoarthritis Initiative (OAI) public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners.
http://onlinelibrary.wiley.com/doi/10.1002/art.42316/abs
.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.42316